SuperworthCorvus Pharmaceuticals EPS CRVS
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- −$0.61
- Latest quarter, Q2 FY26
- −$0.19
- Fiscal year 2025
- −$0.50
Corvus Pharmaceuticals' earnings per share was −$0.61 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.50 | n/a |
| FY2024 | −$0.97 | n/a |
| FY2023 | −$0.57 | n/a |
| FY2022 | −$0.89 | n/a |
| FY2021 | −$1.06 | n/a |
| FY2020 | −$0.21 | n/a |
| FY2019 | −$1.59 | n/a |
| FY2018 | −$1.75 | n/a |
| FY2017 | −$2.72 | n/a |
| FY2016 | −$6.88 | n/a |
| FY2015 | −$86.14 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.19 | n/a | −$0.61 | |
| Q1 FY26 | −$0.15 | n/a | −$0.52 | |
| Q4 FY25 | −$0.15 | n/a | −$0.50 | |
| Q3 FY25 | −$0.12 | n/a | −$0.53 | |
| Q2 FY25 | −$0.10 | n/a | −$1.01 | |
| Q1 FY25 | −$0.13 | n/a | −$0.98 | |
| Q4 FY24 | −$0.18 | n/a | −$0.97 | |
| Q3 FY24 | −$0.60 | n/a | −$0.93 | |
| Q2 FY24 | −$0.07 | n/a | −$0.45 | |
| Q1 FY24 | −$0.12 | n/a | −$0.52 | |
| Q4 FY23 | −$0.14 | n/a | −$0.57 | |
| Q3 FY23 | −$0.12 | n/a | −$0.64 |
Against its peers
Companies in Drug Manufacturers - General nearest Corvus Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CRVSCorvus Pharmaceuticals | −$0.61 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Corvus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.